Recent Updates
Recently added Catalysts
GMED Negative Sentiment Score: 25/100

GLOBUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Globus Medical, Inc. on Behalf of Globus Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Globus Medical, Inc. on behalf of stockholders following the company's disclosure of receiving a warning letter from the FDA. This letter outlines deficiencies concerning the company's response to past FDA inspections, particularly related to product complaint procedures linked to the ExcelsiusGPS robotic system. The warning has resulted in a significant drop in Globus' stock price, prompting concerns over potential legal repercussions and compliance issues. Investors are encouraged to reach out to the law firm if they have relevant information or have suffered losses.

Market Sentiment Analysis

CONCERNS & RISKS

  • Globus Medical received a warning letter from the FDA citing deficiencies in compliance.
  • The company's stock price fell 7.84% following the FDA warning disclosure.
  • The investigation concerns potential violations of federal securities laws.

Full Press Release Details

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Globus Medical, Inc. (“Globus” or the “Company”) (NYSE:GMED) on behalf of Globus stockholders. Our investigation concerns whether Globus has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On August 13, 2024, in a filing with the U.S. Securities and Exchange Commission, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania. In the warning letter, the FDA cited deficiencies in the response letters sent by the Company to the FDA following the Form 483, List of Investigational Observations, which was delivered to the Company in connection with the inspection that occurred from February 15, 2024 until March 7, 2024. The letter describes observed non-conformities in establishing and maintaining product complaint procedures, including complaint investigations, trending, risk reconciliation, and Medical Device Report (MDR) procedures including timely reporting, pertaining to the ExcelsiusGPS® robotic system."
Following disclosure of the FDA's warning letter, Globus's stock price fell $5.73 per share, or 7.84%, to close at $67.32 per share on August 13, 2024.
If you purchased or otherwise acquired Globus shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is Bragar Eagel & Squire investigating?

They are examining potential claims against Globus Medical for possible securities law violations.

What triggered the stock price drop for Globus?

The stock price fell after the FDA issued a warning letter regarding compliance issues.

When did the FDA inspect Globus Medical's facilities?

The FDA inspection occurred between February 15 and March 7, 2024.

Who should contact Bragar Eagel & Squire?

Current or former Globus stockholders who suffered losses or have relevant information.

Last updated: Aug 20, 2024